Cancer research at BESSY II: Binding Mechanisms of Therapeutic Substances Deciphered
The study is displayed on the cover of the journal Chemmedchem. © Chemmedchem/VCH Wiley
In tumor cells, the DNA is altered in comparison to normal body cells. How such changes can be prevented or inhibited is an exciting field of research with great relevance for the development of cancer treatments. An interdisciplinary team has now analysed the possible binding mechanisms in certain therapeutic substances from the tetrazole hydrazide group using protein crystallography at BESSY II.
Certain proteins such as human histone demethylases, including the KDM4 protein, play a role in the development of tumour cells. They bind to the DNA and modify it so that the cell can become cancerous. Therapeutic substances that are able to inhibit or even reverse such changes are of particular interest.
Biochemist Prof. Dr. Udo Heinemann from the Max Delbrück Centre in Berlin-Buch is investigating such processes. In cooperation with chemists led by Prof. Dr. Andreas Link from the University of Greifswald and the team led by Dr. Manfred Weiss at the HZB, he has now investigated how and where certain therapeutic substances from the tetrazole hydrazide group dock to these protein molecules and thus inhibit their harmful effect.
KDM4 protein crystals analysed
Link initially produced variations of tetrazole hydrazide substances. For structural analysis, crystals had to be grown from KDM4 proteins - a difficult task that Dr. Piotr Malecki and Manfred Weiss had taken on at the HZB. The KDM4 protein crystals were then soaked in a specific substance before being analyzed with strong X-rays on the MX beamlines of BESSY II. A refined analysis showed not only the three-dimensional architecture of the KDM4 protein, but also exactly where the active substances had docked to the KDM4 molecule.
"This class of substances has not yet been structurally investigated," explains Manfred Weiss. And Udo Heinemann from the MDC explains: "We will now evaluate where there are opportunities to dock even stronger within the 3D structure of the KDM4. Then we might also be able to develop drugs that inhibit the KDM4 even more and thus have the potential to become a therapeutic."
- HZB congratulates Peter Hegemann on winning the Nobel PrizeOur warmest congratulations go to Peter Hegemann, Professor of Neuroscience and Experimental Biophysics at Humboldt University in Berlin. Together with Prof. Georg Nagel (Julius Maximilian University of Würzburg) and Prof. Karl Deisseroth (Stanford University, USA), he has been awarded the 2026 Nobel Prize in Physiology or Medicine. We are delighted for him, his team, Humboldt University and the entire Berlin scientific community.
- Science in Berlin: collaborative, diverse, innovative, internationalScience is a key social and economic factor for Berlin. It creates jobs and adds value, attracts talent from all over the world, and enriches city life. To ensure that Berlin remains one of the world’s leading centres of science in the future, science must feature even more prominently on the political agenda. This is what BR50 stands for: over 50 non-university research institutions, including the HZB, are joining forces in this network. Following the election in Berlin, BR50 is now addressing politicians with a position paper, accompanied by the campaign “𝗪𝗶𝗿 𝗳𝗼𝗿𝘀𝗰𝗵𝗲𝗻 𝗳ü𝗿 𝗕𝗲𝗿𝗹𝗶𝗻.”
- Does African Architecture exist?The world’s first Pan-African Architecture Biennale took place this September in Nairobi, Kenya. People from the worlds of architecture, art, academia and politics from 54 African countries and the diaspora had travelled to Nairobi to exchange ideas on traditional and contemporary building methods, materials, experiences and projects. Samira Aden co-organised this biennial as lead curator. We spoke to her about it.